[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ratika Parkash\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100535241","reversal-of-atrial-substrate-to-prevent-atrial-fibrillation-cohort-study-100535241",false,"NCT06249269","Reversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study","RASTA-Cohort","Inclusion Criteria:\n\n* symptomatic AF (CCS-SAF ≥2),\n* paroxysmal or persistent atrial fibrillation despite rate control, desiring catheter ablation and either: i) BMI ≥ 30 or, ii) at least two of the following: BMI\\>27, BP\\>140\u002F90 mmHg or history of hypertension, Diabetes, Heart failure (prior heart failure admission or LVEF\\\u003C40%), Age ≥ 65 years, Prior stroke\u002FTIA, Current smoker, Excessive alcohol use {For women: 10 or more drinks\u002Fweek, more than 2 drinks a day (most days). For men: 15 or more drinks\u002Fweek, more than 3 drinks a day (most days)}, and iii) declined or were not approached for participation in the main study. Eligible patients must have received catheter ablation for AF during the same timeline of the RASTA-AF Mian Study (November 1st, 2019 to December 31st, 2025).\n\nExclusion Criteria:\n\n* permanent AF (AF lasting \\> 3 years),\n* prior catheter ablation for AF\n* New York Heart Association Class IV heart failure\n* participation in a cardiac rehabilitation program within the last year,\n* currently performing exercise training \\>150 minutes\u002Fweek of moderate to vigorous physical activity,\n* unable to exercise,\n* unable to give informed consent,\n* other noncardiovascular medical condition making 1 year survival unlikely\n* less than 18 years of age","ALL","18 Years",{"count":19,"type":20},198,"ESTIMATED","2 Years","OBSERVATIONAL","Atrial fibrillation (AF) is a major health problem, with a prevalence of 0.4-1% of the population. It results in high healthcare costs and significant morbidity, especially for patients with severe symptoms. The RASTA-AF randomized control trial (RCT) is designed to answer the following question: does vigorous treatment of AF with aggressive risk factor management plus catheter ablation reduce AF-related outcomes as compared to catheter ablation plus usual care in patients with symptomatic AF and risk factors that promote AF.\n\nThis study is a multicenter, prospective cohort study that will enrol patients who decline participation in the RASTA-AF RCT but agree to be followed in a registry. The objective of RASTA-Cohort is to determine whether patients who decline participation in the RASTA-AF RCT have different clinical characteristics and quality of life than patients who accept participation in the study, and whether they suffer from worse AF-related outcomes than patients in the RCT.",[25],"Atrial Fibrillation, Paroxysmal or Persistent","RECRUITING","2025-11-25",{"date":29,"type":30},"2025-12-02","ACTUAL",{"date":32,"type":30},"2024-05-01",{"date":34,"type":20},"2027-03",{"name":36,"class":37},"Ratika Parkash","OTHER",7,""]